Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

The Biological Reference Repository (BioR): a rapid and flexible system for genomics annotation
Kocher, Jean-Pierre A., Quest, Daniel, Meiners, Michael A., Moore, Raymond M. , Hossain, Asif, Hart, Steven N. , Dinu, Valentin , Quest, Daniel J, Duffy, Patrick, Rider, David, Duffy, Patrick Emmet , Rider, David A. , Dinu, Valentin , Hart, Steven N , Moore, Raymond

Bioinformatics | March 12, 2014 | Volume: 30 | Issue: 13 | Pages: 1920-1922

10.1093/bioinformatics/btu137 | PMID 24618464 Get It

Abstract Motivation: The Biological Reference Repository (BioR) is a toolkit for annotating variants. BioR stores public and user-specific annotation sources in indexed JSON-encoded flat files (catalogs). The BioR toolkit provides the functionality to combine and retrieve annotation from these catalogs via the command-line interface. Several catalogs from commonly used annotation sources and instructions for creating user-specific catalogs are provided. Commands from the toolkit can be combined with other UNIX commands for advanced annotation processing. We also provide instructions for the development of custom annotation pipelines. Availability and implementation: The package is implemented in Java and makes use of external tools written in Java and Perl. The toolkit can be executed on Mac OS X 10.5 and above or any Linux distribution. The BioR application, quickstart, and user guide documents and many biological examples are available at http://bioinformaticstools.mayo.edu . Contact: Kocher.JeanPierre@mayo.edu Supplementary information: Supplementary data are available at Bioinformatics online.
Infection and Inflammation Leading to Clozapine Toxicity and Intensive Care
Leung, Jonathan G. , Nelson, Sarah , Takala, Christopher R., Gören, Jessica L. , Leung, Jonathan G

Annals of Pharmacotherapy | March 11, 2014 | Volume: 48 | Issue: 6 | Pages: 801-805

10.1177/1060028014526701 | PMID 24619948 Get It

Objective: To describe 3 cases of clozapine toxicity associated with infectious and/or inflammatory processes. Case Summaries: Three patients stable on clozapine therapy prior to a medical hospital admission developed clozapine toxicity. It was suspected that an acute infectious and/or inflammatory process in each patient was related to abrupt mental status changes, onset of sialorrhea, myoclonus, and/or need for ventilatory support. Investigations of altered mental status did not reveal alternative causes and presentations were not consistent with neuroleptic malignant syndrome, other acute neurologic complications, or psychiatric decompensation. All patients improved after clozapine dose reductions allowing for transfer from intensive care units. Using the Naranjo ADR Probability Scale for each case, a probable relation between clozapine toxicity and the infectious and/or inflammatory process was determined. Discussion: Clozapine toxicity may manifest with multiple symptoms, including sedation, sialorrhea, and hypotension. In addition to overdose and drug interactions; infection and/or inflammation may precipitate clozapine toxicity. This may be related to cytokine-mediated inhibition of cytochrome P450 1A2. The likelihood of toxicity via this mechanism has not been well characterized, thus careful monitoring is required for medically ill patients receiving clozapine. Clozapine is extensively bound to the acute phase reactant, α-1 acid glycoprotein, which may unpredictably protect against clinical toxicity. C-reactive protein has also been investigated to relate clozapine toxicity to infection and/or inflammation. Conclusion: Clozapine toxicity developed in 3 patients admitted to a medical setting suspected to be related to infection and/or inflammation. Clinicians should be aware of this potential adverse drug event with clozapine.
Mass Spectrometry Measurements of Prostate-Specific Antigen (PSA) Peptides Derived From Immune-Extracted PSA Provide a Potential Strategy for Harmonizing Immunoassay Differences
Klee, Eric W. , Bondar, Olga P., Goodmanson, Marcia K., Trushin, Sergey A., Anderson, N. Leigh , Klee, George G., Singh, Ravinder J.

American Journal of Clinical Pathology | March 11, 2014 | Volume: 141 | Issue: 4 | Pages: 527-533

10.1309/ajcp8pel0yxahdvk | PMID 24619754 Get It

Faculty Opinions recommendation of Highly efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair.
Ekker, Stephen C.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 11, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718163370.793491773 Get It

North Central Cancer Treatment Group/Alliance trial N08CA—the use of glutathione for prevention of paclitaxel/carboplatin‐induced peripheral neuropathy: A phase 3 randomized, double‐blind, placebo‐controlled study
Leal, Alexis D. , Qin, Rui , Atherton, Pamela J. , Haluska, Paul , Behrens, Robert J. , Tiber, Charles H., Watanaboonyakhet, Patanit, Weiss, Matthias , Adams, Paul T., Dockter, Travis , Loprinzi, Charles L.

Cancer | March 11, 2014 | Volume: 120 | Issue: 12 | Pages: 1890-1897

10.1002/cncr.28654 | PMID 24619793 Get It

BACKGROUNDChemotherapy‐induced peripheral neuropathy (CIPN) is a significant side effect of taxane and platinum‐based chemotherapy. Several studies have supported the potential benefit of glutathione for the prevention of platinum‐induced CIPN. The current trial was designed to determine whether glutathione would prevent CIPN as a result of carboplatin/paclitaxel therapy.METHODSIn total, 185 patients who received treatment with paclitaxel and carboplatin were accrued between December 4, 2009 and December 19, 2011. Patients were randomized to receive either placebo (n = 91) or 1.5 g/m2 glutathione (n = 94) over 15 minutes immediately before chemotherapy. CIPN was assessed using the European Organization for Research and Treatment of Cancer Quality‐of‐Life (EORTC‐QLQ) 20‐item, CIPN‐specific (CIPN20) sensory subscale and the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.RESULTSThere were no statistically significant differences between the 2 study arms with regard to: 1) peripheral neurotoxicity, as assessed using both the EORTC‐QLQ‐CIPN20 (P = .21) and the CTCAE scales (P = .449 for grade ≥2 neurotoxicity; P = .039 for time to development of grade ≥2 neuropathy, in favor of the placebo); 2) the degree of paclitaxel acute pain syndrome (P = .30 for patients who received paclitaxel every 3‐4 weeks and P = .002, in favor of the placebo, for patients who received weekly paclitaxel); 3) the time to disease progression (P = .63); or 4) apparent toxicities. Subgroup analyses did not reveal any evidence of benefit in any particular subgroup.CONCLUSIONSThe results from this study do not support the use of glutathione for the prevention of paclitaxel/carboplatin‐induced CIPN. Cancer 2014;120:1890–1897. © 2014 American Cancer Society.
Radiologist's perspective for the Meckel's diverticulum and its complications
Kotha, Vamshi, Saboo, Sachin S. , Shanbhogue, Krishna , Virmani, Vivek, Marginean, Esmeralda Celia, Menias, Christine O. , Khandelwal, Ashish

The British Journal of Radiology | March 11, 2014 | Volume: 87 | Issue: 1037 | Pages: No page available

10.1259/bjr.20130743 | PMID 24611767 Get It

The Meckel's diverticulum is the commonest congenital anomaly of the gastrointestinal tract, often presenting with complications such as gastrointestinal bleeding, intussusception, bowel obstruction and diverticulitis, which are often misdiagnosed. Imaging plays an important role in the early diagnosis and characterization of these conditions and is very helpful in decision making. The Meckel's diverticulum and its complications have myriad presentations and appearances on various imaging modalities. Thus, sound knowledge of the anatomy, embryology, clinical presentation, imaging characteristics and complications is crucial to the practice of abdominal imaging. We present a review of the literature and current radiological practices in the diagnosis and management of the Meckel's diverticulum and its various complications with special emphasis on the imaging of various complications, mimickers and pathological correlation.
Satisfaction With Work-Life Balance and the Career and Retirement Plans of US Oncologists
Raymond, Marilyn, Kosty, Michael P., Satele, Daniel , Horn, Leora , Pippen, John , Chu, Quyen D. , Chew, Helen K. , Clark, William B., Hanley, Amy, Sloan, Jeff A. , Gradishar, William J. , Shanafelt, Tait D.

Journal of Clinical Oncology | March 11, 2014 | Volume: 32 | Issue: 11 | Pages: 1127-1135

10.1200/jco.2013.53.4560 | PMID 24616305 Get It

Purpose To evaluate satisfaction with work-life balance (WLB) and career plans of US oncologists. Methods The American Society of Clinical Oncology conducted a survey of US oncologists evaluating satisfaction with WLB and career plans between October 2012 and March 2013. The sample included equal numbers of men and women from all career stages. Results Of 2,998 oncologists contacted, 1,490 (49.7%) returned surveys. From 1,117 oncologists (37.3% of overall sample) completing full-length surveys, we evaluated satisfaction with WLB and career plans among the 1,058 who were not yet retired. The proportion of oncologists satisfied with WLB (n = 345; 33.4%) ranked lower than that reported for all other medical specialties in a recent national study. Regarding career plans, 270 oncologists (26.5%) reported a moderate or higher likelihood of reducing their clinical work hours in the next 12 months, 351 (34.3%) indicated a moderate or higher likelihood of leaving their current position within 24 months, and 273 (28.5%) planned to retire before 65 years of age. Multivariable analyses found women oncologists (odds ratio [OR], 0.458; P < .001) and those who devoted greater time to patient care (OR for each additional hour, 0.977; P < .001) were less likely to be satisfied with WLB. Satisfaction with WLB and burnout were the strongest predictors of intent to reduce clinical work hours and leave current position on multivariable analysis. Conclusion Satisfaction with WLB among US oncologists seems lower than for other medical specialties. Dissatisfaction with WLB shows a strong relationship with plans to reduce hours and leave current practice. Given the pending US oncologist shortage, additional studies exploring interactions among WLB, burnout, and career satisfaction and their impact on career and retirement plans are warranted.
Eosinophils Regulate Peripheral B Cell Numbers in Both Mice and Humans
Wong, Tina W., Doyle, Alfred D. , Lee, James J. , Jelinek, Diane F.

The Journal of Immunology | March 11, 2014 | Volume: 192 | Issue: 8 | Pages: 3548-3558

10.4049/jimmunol.1302241 | PMID 24616476 Get It

Abstract The view of eosinophils (Eos) as solely effector cells involved in host parasite defense and in the pathophysiology of allergic diseases has been challenged in recent years. In fact, there is a growing realization that these cells interact with other components of innate and adaptive immunity. For example, mouse Eos were recently demonstrated to promote plasma cell retention in the bone marrow. However, it remains unknown whether Eos influence the biology of normal B lymphocytes. In this study, we specifically assessed the effect of Eos on B cell survival, proliferation, and Ig secretion. Our data first revealed that the genetic deletion of Eos from NJ1638 IL-5 transgenic hypereosinophilic mice (previously shown to display profound B cell expansion) resulted in the near abolishment of the B cell lymphocytosis. In vitro studies using human tissues demonstrated Eos’ proximity to B cell follicles and their ability to promote B cell survival, proliferation, and Ig secretion via a contact-independent mechanism. Additionally, this ability of Eos to enhance B cell responsiveness was observed in both T-independent and T-dependent B cell activation and appears to be independent of the activation state of Eos. Finally, a retrospective clinical study of hypereosinophilic patients revealed a direct correlation between peripheral blood eosinophil levels and B cell numbers. Taken together, our study identifies a novel role for Eos in the regulation of humoral immunity via their impact on B cell homeostasis and proliferation upon activation.
Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives
Win, Aung Ko , Buchanan, Daniel D. , Rosty, Christophe , MacInnis, Robert J. , Dowty, James G. , Dite, Gillian S. , Giles, Graham G. , Southey, Melissa C. , Young, Joanne , Walsh, Michael D. , Walters, Rhiannon, Boussioutas, Alex , Smyrk, Thomas C. , Thibodeau, Stephen N. , Potter, John D. , Marchand, Loı̈c Le, Haile, Robert W. , Gallinger, Steven, Lindor, Noralane M. , Ahnen, Dennis J. , Jenkins, Mark A. , Clendenning, Mark , Baron, John A. , Newcomb, Polly A. , Hopper, John L. , Buchanan, Daniel D , Win, Aung K , Giles, Graham G , Southey, Melissa C , Jenkins, Mark A , Haile, Robert W , Maclnnis, Robert , Potter, John D , Rosty, Christophe

Gut | March 11, 2014 | Volume: 64 | Issue: 1 | Pages: 101-110

10.1136/gutjnl-2013-306567 | PMID 24615377 Get It

Objective To estimate risk of colorectal cancer (CRC) for first-degree relatives of CRC cases based on CRC molecular subtypes and tumour pathology features. Design We studied a cohort of 33 496 first-degree relatives of 4853 incident invasive CRC cases (probands) who were recruited to the Colon Cancer Family Registry through population cancer registries in the USA, Canada and Australia. We categorised the first-degree relatives into four groups: 28 156 of 4095 mismatch repair (MMR)-proficient probands, 2302 of 301 MMR-deficient non-Lynch syndrome probands, 1799 of 271 suspected Lynch syndrome probands and 1239 of 186 Lynch syndrome probands. We compared CRC risk for first-degree relatives stratified by the absence or presence of specific tumour molecular pathology features in probands across each of these four groups and for all groups combined. Results Compared with first-degree relatives of MMR-proficient CRC cases, a higher risk of CRC was estimated for first-degree relatives of CRC cases with suspected Lynch syndrome (HR 2.06, 95% CI 1.59 to 2.67) and with Lynch syndrome (HR 5.37, 95% CI 4.16 to 6.94), but not with MMR-deficient non-Lynch syndrome (HR 1.04, 95% CI 0.82 to 1.31). A greater risk of CRC was estimated for first-degree relatives if CRC cases were diagnosed before age 50 years, had proximal colon cancer or if their tumours had any of the following: expanding tumour margin, peritumoral lymphocytes, tumour-infiltrating lymphocytes or synchronous CRC. Conclusions Molecular pathology features are potentially useful to refine screening recommendations for first-degree relatives of CRC cases and to identify which cases are more likely to be caused by genetic or other familial factors.